24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade

24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade

Bibliographic Details
Main Author: Pashtoon Kasi
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-3ece150fd8be40f0aa5f8ef7dee2d9a4
record_format Article
spelling doaj-3ece150fd8be40f0aa5f8ef7dee2d9a42020-12-11T10:00:48ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.002424 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockadePashtoon Kasi0University of Iowa, Iowa City, IA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Pashtoon Kasi
spellingShingle Pashtoon Kasi
24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
Journal for ImmunoTherapy of Cancer
author_facet Pashtoon Kasi
author_sort Pashtoon Kasi
title 24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
title_short 24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
title_full 24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
title_fullStr 24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
title_full_unstemmed 24 Utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
title_sort 24 utility of tumor-informed molecular residual disease assays in patients with complete response to immune checkpoint blockade
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT pashtoonkasi 24utilityoftumorinformedmolecularresidualdiseaseassaysinpatientswithcompleteresponsetoimmunecheckpointblockade
_version_ 1724386650312671232

Similar Items